Bliss GVS Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on May 12, 2025.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with an unmodified auditor opinion. On a consolidated basis, total income rose about 5.9% to Rs. 84,621.97 Lakh and net profit grew around 10.6% to Rs. 9,025.53 Lakh. Standalone performance was stronger, with net profit jumping roughly 36% to Rs. 6,896.87 Lakh. The board recommended a final dividend of Rs. 0.50 per equity share (50% on face value of Rs. 1) subject to shareholder approval at the 40th AGM on July 31, 2025. The company also approved the sale of its 51% stake in step-down subsidiary Greenlife Bliss Healthcare Ltd (Nigeria) to the existing non-controlling shareholder, Greenlife Pharmaceuticals Limited, for USD 13 lakh, and the issuance of 12.10 lakh sweat equity shares to the Managing Director and Vice President at Rs. 148.72 per share. BDO India LLP was re-appointed as Internal Auditor and AVS & Associates was appointed as Secretarial Auditor for five years.
Modest consolidated growth may limit upside excitement, though the sharp standalone PAT jump and continued dividend signal stability. The related-party sale of a loss-making Nigerian subsidiary simplifies the group structure but is relatively small in value. The sweat equity allotment to the MD and VP is mildly dilutive and will be closely watched by minority shareholders.